Aktis Oncology (NASDAQ:AKTS) Shares Gap Down – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $19.55, but opened at $18.50. Aktis Oncology shares last traded at $18.7050, with a volume of 9,999 shares trading hands.

Analysts Set New Price Targets

A number of analysts have weighed in on AKTS shares. Weiss Ratings started coverage on shares of Aktis Oncology in a research report on Tuesday, May 12th. They issued a “sell (d)” rating on the stock. William Blair started coverage on shares of Aktis Oncology in a research report on Wednesday, April 29th. They issued an “outperform” rating on the stock. Leerink Partners started coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 target price on the stock. Bank of America started coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Aktis Oncology Trading Up 2.9%

The stock’s fifty day simple moving average is $18.65.

Aktis Oncology (NASDAQ:AKTS) last released its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The company had revenue of $1.87 million for the quarter. Equities research analysts forecast that Aktis Oncology will post -1.56 earnings per share for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.